Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Ron MartellPresident and CEO | Jasper TherapeuticsJSPR | Open-market buy | 25/09/22 | 25/09/24 | 41,000 sh | $2.43 | $99,630 | +123.8% |
Thomas G. WiggansDirector | Jasper TherapeuticsJSPR | Open-market buy | 25/09/22 | 25/09/24 | 41,000 sh | $2.43 | $99,630 | No record |
Svetlana LucasDirector | Jasper TherapeuticsJSPR | Open-market buy | 25/09/22 | 25/09/24 | 20,000 sh | $2.43 | $48,600 | No record |
Judith Anne ShizuruDirector | Jasper TherapeuticsJSPR | Open-market buy | 25/09/22 | 25/09/24 | 41,000 sh | $2.43 | $99,630 | +35.4% |
Jasper TherapeuticsJSPR | Open-market sale10b5-1 plan | 24/12/12 | 24/12/12 | 900 sh | $22.11 | $19,899 | −3.5% | |
Jasper TherapeuticsJSPR | Open-market sale10b5-1 plan | 24/09/12 | 24/09/12 | 900 sh | $21.23 | $19,107 | −3.5% | |
Jasper TherapeuticsJSPR | Open-market sale10b5-1 plan | 24/06/12 | 24/06/12 | 900 sh | $24.16 | $21,744 | −3.5% | |
Jasper TherapeuticsJSPR | Open-market sale | 24/03/12 | 24/03/12 | 900 sh | $26.44 | $23,796 | −3.5% | |
TC Group10% Owner | Jasper TherapeuticsJSPR | Open-market buy | 24/02/08 | 24/02/12 | 190,000 sh | $12.95 | $2,460,500 | +21.7% |
Balaji Venkataraman10% Owner | Jasper TherapeuticsJSPR | Open-market buy | 24/02/08 | 24/02/09 | 350,000 sh | $12.95 | $4,532,500 | +41.7% |
Thomas G. WiggansDirector | Jasper TherapeuticsJSPR | Open-market buy | 23/11/28 | 23/11/30 | 10,000 sh | $0.65 | $6,500 | +25.0% |
Thomas G. WiggansDirector | Jasper TherapeuticsJSPR | Open-market buy | 23/11/21 | 23/11/22 | 10,000 sh | $0.64 | $6,400 | +33.3% |
Jasper TherapeuticsJSPR | Open-market buy | 23/11/16–23/11/20 | 23/11/20 | 30,000 sh3 trades | $0.61avg. | $18,300 | No record | |
Lis WilliamDirector | Jasper TherapeuticsJSPR | Open-market sale10b5-1 plan | 23/10/13 | 23/10/13 | 7,965 sh | $0.85 | $6,770.25 | −13.0% |
Jeetinder Singh MahalSEE REMARKS | Jasper TherapeuticsJSPR | Open-market sale10b5-1 plan | 23/06/13 | 23/06/13 | 9,000 sh | $1.66 | $14,940 | −3.0% |
Anna Louise FrenchDirector | Jasper TherapeuticsJSPR | Open-market sale | 23/04/14 | 23/04/14 | 7,000 sh | $1.48 | $10,360 | −22.8% |
Kurt Von EmsterDirector | Jasper TherapeuticsJSPR | Open-market sale | 23/04/13 | 23/04/14 | 9,075 sh | $1.49 | $13,521.75 | −30.0% |
Lis WilliamDirector | Jasper TherapeuticsJSPR | Open-market sale | 23/04/13 | 23/04/14 | 8,500 sh | $1.44 | $12,240 | −12.1% |
Mark McDade10% Owner | Jasper TherapeuticsJSPR | Open-market buy | 23/01/27 | 23/04/11 | 2,666,666 sh | $1.50 | $3,999,999 | +45.6% |
TC Group10% Owner | Jasper TherapeuticsJSPR | Open-market buy | 23/01/27 | 23/01/31 | 3,133,333 sh | $1.50 | $4,699,999.5 | +55.7% |